Siteone Therapeutics, Inc.
- UEI
- ZKBYHMUQS291
- CAGE
- 61AQ1
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a potent and selective NAV1.8 inhibitor for the treatment of acute and chronic pain with the goal of… | National Institute on Drug Abuse | $10,683,334 | |
| Development of a selective inhibitor of NAV1.7 for the treatment of ocular pain - project summary the absence of safe… | National Eye Institute | $4,185,151 | |
| Development of a potent and highly selective NAV1.7 inhibitor for the treatment of acute pain with the goal of… | National Institute on Drug Abuse | $5,368,397 | |
| Development of NAV1.7 selective inhibitors for the treatment of chronic cough - project summary chronic cough, or… | National Heart Lung and Blood Institute | $4,293,135 | |
| Discovery of NAV1.7 inhibitors for the treatment of pain | National Institute of Neurological Disorders and Stroke | $2,050,425 |
About Siteone Therapeutics, Inc.
Siteone Therapeutics, Inc. is a for-profit biotechnology company focused on developing novel medicines for the treatment of pain. Through a series of federal grants from the National Institutes of Health, the company has advanced selective inhibitors of voltage-gated sodium ion channels implicated in pain signaling for multiple therapeutic applications.
Specifically, Siteone has received over $27 million in federal funding to support preclinical and clinical development programs for Nav1.7 and Nav1.8 inhibitors aimed at reducing acute and chronic pain. Awards have been issued under cooperative agreements and project grants from the National Institute on Drug Abuse, National Eye Institute, National Heart Lung and Blood Institute, and National Institute of Neurological Disorders and Stroke. These programs span treatment of postoperative, neuropathic and ocular pain, as well as chronic cough. If successful, Siteone's selective sodium channel blockers could provide effective alternatives to opioid analgesics and conventional local anesthetics. Current projects are focused on completing investigational new drug-enabling studies and early stage clinical trials to evaluate safety, tolerability and therapeutic potential across multiple pain indications.
Quick answers
What is Siteone Therapeutics, Inc.'s UEI?
Siteone Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is ZKBYHMUQS291.
What is Siteone Therapeutics, Inc.'s CAGE code?
Siteone Therapeutics, Inc.'s CAGE code is 61AQ1.
What is Siteone Therapeutics, Inc.'s primary NAICS code?
Siteone Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Siteone Therapeutics, Inc. registered in SAM.gov?
Siteone Therapeutics, Inc.'s SAM.gov registration expired on November 19, 2025.
What is Siteone Therapeutics, Inc.'s most recent federal award?
Siteone Therapeutics, Inc.'s most recent federal grant award is Development of a potent and selective NAV1.8 inhibitor for the treatment of acute and chronic pain with the goal of… (UG3DA058552), from National Institute on Drug Abuse, on May 15, 2023.
On GovTribe
See Siteone Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors